A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia
无蒂锯齿状息肉和随后的结直肠肿瘤的队列研究
基本信息
- 批准号:9039561
- 负责人:
- 金额:$ 58.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-22 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenocarcinomaAdenomatous PolypsAffectAppearanceBRAF geneBiological MarkersCACNA1G geneCaliberCancer PatientCaringCase SeriesCharacteristicsClinicalClinical ManagementClinical TrialsCohort StudiesColonColon CarcinomaColonoscopyColorectalColorectal CancerColorectal NeoplasmsColorectal PolypConsensusCpG Island Methylator PhenotypeDNADataDetectionDevelopmentDiagnosisDysplasiaEffectivenessExcisionExhibitsGoalsGuidelinesHealthHigh PrevalenceHyperplastic PolypIGF2 geneIncidenceIndividualLarge Intestine CarcinomaLesionLiteratureLocationLongitudinal StudiesMalignant - descriptorMalignant NeoplasmsMedical RecordsMedical SurveillanceMethylationMolecularMutationNeoplasmsNomenclatureOutcomePathologyPathway interactionsPatientsPolypsPublic HealthRecommendationRegimenRiskSerrated AdenomaSystemTestingTimeTissuesTooth structureTriageUnited StatesVillousWashingtonWomanWorkabstractingadenomaagedbasecase controlclinical Diagnosisclinically significantcohortcolonic cryptcolorectal cancer screeningcomparison groupdemographicsevidence based guidelinesfollow-uphealth care deliveryhigh riskimprovedmembermenmortalityneoplasm registrypatient populationpotential biomarkerpreventscreeningtumorvigilance
项目摘要
DESCRIPTION (provided by applicant): Colorectal cancer screening guidelines currently focus on the detection and removal of advanced adenomatous polyps. However, recent evidence implicates an additional group of polyps, sessile serrated polyps (SSPs), as important precursors to colorectal cancer that may also warrant increased vigilance. SSPs were previously grouped with hyperplastic polyps (HPs), lesions routinely believed to have no malignant potential. Now, there is growing consensus that SSPs belong on the "serrated pathway" to colorectal cancer. Tumors resulting from this pathway are usually located in the proximal colon, characterized as having a CpG island methylator phenotype (CIMP), and often exhibit mutations in BRAF. The long term goal of this study is to characterize new high-risk groups to improve the effectiveness of colorectal cancer screening. In working towards this goal, we propose a study to examine the clinical significance of SSPs that addresses the following specific aims: 1) determine the risk of subsequent colorectal neoplasia associated with SSPs relative to HPs and polyp-free controls; 2) evaluate whether the risk of subsequent neoplasia associated with SSPs varies according to polyp characteristics, such as size, proximal location, and the number of SSPs; 3) determine the association between molecular characteristics of SSPs and HPs, such as BRAF-mutation and CIMP-status, and risk of subsequent colorectal neoplasia. To accomplish these aims, we propose a retrospective cohort study among 7,800 members of the integrated healthcare delivery system, Group Health (GH). Men and women, aged 24-74, who received a baseline colonoscopy from 1998-2007 and had a clinical diagnosis of HPs (N=3,900) and a comparison group of colonoscopy patients with no colorectal pathology at baseline (N=3,900) will be eligible for this study. Cohort members with clinically diagnosed HPs at baseline will undergo a standard pathology review, developed and validated in our prior studies of colorectal polyps, to confirm the diagnosis and to distinguish SSPs according to standard histological criteria. Medical records will be abstracted to gather data on baseline polyp
characteristics and cohort member demographics. Linkage to the Western Washington Surveillance, Epidemiology, and End Results cancer registry and GH medical records through January 1, 2013 will be used to retrospectively ascertain incident colorectal polyps and frank colorectal carcinoma. For Aim 3, we will use a nested case-control approach among those with HPs or SSPs at baseline, collect baseline polyp tissue, and test tissue DNA for BRAF mutation using TaqMan PCR and CIMP using a colorectal cancer-specific MethyLight PCR panel (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1). This will be the largest cohort study to evaluate outcomes associated with SSPs and the first to evaluate BRAF- mutation and CIMP-status as potential biomarkers for advanced neoplasia risk. Our study findings will have great public health importance, will provide data to inform clinical trial development, and ultimately affect the way clinicians triage individuals with serrated polyps to different colorectal cancer screening regimens.
描述(由申请人提供):结直肠癌筛查指南目前侧重于晚期腺瘤性息肉的检测和切除。然而,最近的证据表明,另一组息肉,无蒂锯齿状息肉(SSP),作为结直肠癌的重要前体,也可能需要提高警惕。SSP以前被归类为增生性息肉(HP),病变通常被认为没有恶性潜力。现在,越来越多的人认为SSP属于结直肠癌的“锯齿状途径”。由该途径产生的肿瘤通常位于近端结肠,其特征在于具有CpG岛甲基化表型(CIMP),并且通常在BRAF中表现出突变。这项研究的长期目标是描述新的高危人群,以提高结直肠癌筛查的有效性。为了实现这一目标,我们提出了一项研究,以检查SSP的临床意义,解决了以下具体目标:1)确定与Hp和无息肉对照相比,SSP相关的后续结直肠肿瘤形成的风险; 2)评估与SSP相关的后续肿瘤形成的风险是否根据息肉特征而变化,如大小,近端位置和SSP的数量; 3)确定SSP和HP的分子特征(如BRAF突变和CIMP状态)与随后的结直肠肿瘤形成风险之间的关联。为了实现这些目标,我们提出了一个回顾性队列研究的7,800名成员的综合医疗服务系统,组健康(GH)。年龄在24-74岁之间的男性和女性,在1998-2007年接受过基线结肠镜检查并有HP临床诊断(N= 3,900),以及基线时无结直肠病理学的结肠镜检查患者对照组(N= 3,900)将有资格参加本研究。基线时临床诊断为HP的队列成员将接受标准病理学审查,该审查在我们先前的结直肠息肉研究中开发和验证,以确认诊断并根据标准组织学标准区分SSP。将提取医疗记录以收集基线息肉数据
特征和群组成员人口统计学。与西部华盛顿监测、流行病学和最终结果癌症登记处和GH医疗记录(截至2013年1月1日)的联系将用于回顾性确定偶发性结直肠息肉和坦率的结直肠癌。对于目标3,我们将在基线时患有HP或SSP的患者中使用巢式病例对照方法,收集基线息肉组织,并使用TaqMan PCR和CIMP使用结直肠癌特异性MethyLight PCR面板(CACNA 1G,IGF 2,NEUROG 1,RUNX 3和SOCS 1)检测组织DNA的BRAF突变。这将是评价SSP相关结局的最大队列研究,也是首次评价BRAF突变和CIMP状态作为晚期肿瘤风险的潜在生物标志物的研究。我们的研究结果将具有巨大的公共卫生重要性,将提供数据,为临床试验的发展提供信息,并最终影响临床医生将锯齿状息肉患者分诊到不同的结直肠癌筛查方案的方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
POLLY A NEWCOMB其他文献
POLLY A NEWCOMB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('POLLY A NEWCOMB', 18)}}的其他基金
Serrated Colorectal Cancer: An Emerging Disease Subtype
锯齿状结直肠癌:一种新出现的疾病亚型
- 批准号:
8913445 - 财政年份:2015
- 资助金额:
$ 58.67万 - 项目类别:
Research Program: Cancer Epidemiology, Prevention and Control
研究项目:癌症流行病学、预防与控制
- 批准号:
8804795 - 财政年份:2015
- 资助金额:
$ 58.67万 - 项目类别:
Serrated Colorectal Cancer: An Emerging Disease Subtype
锯齿状结直肠癌:一种新出现的疾病亚型
- 批准号:
9064754 - 财政年份:2015
- 资助金额:
$ 58.67万 - 项目类别:
A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia
无蒂锯齿状息肉和随后的结直肠肿瘤的队列研究
- 批准号:
8827709 - 财政年份:2013
- 资助金额:
$ 58.67万 - 项目类别:
A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia
无蒂锯齿状息肉和随后的结直肠肿瘤的队列研究
- 批准号:
8655145 - 财政年份:2013
- 资助金额:
$ 58.67万 - 项目类别:
A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia
无蒂锯齿状息肉和随后的结直肠肿瘤的队列研究
- 批准号:
8452499 - 财政年份:2013
- 资助金额:
$ 58.67万 - 项目类别:
Lipid genotypes, phenotypes, and colorectal adenomas: Elucidating mechanisms
脂质基因型、表型和结直肠腺瘤:阐明机制
- 批准号:
8386849 - 财政年份:2012
- 资助金额:
$ 58.67万 - 项目类别:
Lipid genotypes, phenotypes, and colorectal adenomas: Elucidating mechanisms
脂质基因型、表型和结直肠腺瘤:阐明机制
- 批准号:
8542803 - 财政年份:2012
- 资助金额:
$ 58.67万 - 项目类别:
Cadmium Exposure and Risk of Breast Cancer in the Women's Health Initiative
妇女健康倡议中的镉暴露和乳腺癌风险
- 批准号:
8471111 - 财政年份:2011
- 资助金额:
$ 58.67万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 58.67万 - 项目类别:














{{item.name}}会员




